文献速递乳腺腹部MR

锰基磁共振对比剂Mn-PyC3A的肿瘤对比增强与全身清除

Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A.
PubMed 文献 · Invest Radiol · 2019-01-01

在小鼠乳腺癌和肝转移模型中,比较Mn-PyC3A与Gd-DOTA及Gd-EOB-DTPA的肿瘤对比增强效果,并定量大鼠体内Mn-PyC3A的排泄与组织残留。Mn-PyC3A的肿瘤对比增强与Gd-DOTA相当,且比Gd-DOTA更完全地被清除;其部分肝胆排泄使肝转移灶在延迟期清晰可见。

要点

  • Mn-PyC3A在乳腺肿瘤模型的对比增强与Gd-DOTA相当。
  • Mn-PyC3A经尿排泄85%、经粪便排泄15%。
  • Mn-PyC3A的组织残留低于Gd-DOTA,1天和7天均如此。

核心结论

  • Mn-PyC3A在小鼠乳腺癌模型中提供与Gd-DOTA相当的肿瘤对比增强,且比Gd-DOTA更完全地被清除;Mn-PyC3A的部分肝胆排泄使肝转移灶在延迟期清晰可见。

研究设计与样本

  • 研究论文;小鼠乳腺癌模型(n=8)比较0.1 mmol/kg Mn-PyC3A与0.1 mmol/kg Gd-DOTA;小鼠肝转移模型(n=6)比较Mn-PyC3A与0.025 mmol/kg Gd-EOB-DTPA;大鼠注射2.0 mmol/kg [Mn]Mn-PyC3A或Gd-DOTA后定量排泄、1天和7天生物分布。

关键影像表现/征象

  • 注射后3分钟,Mn-PyC3A与Gd-DOTA的肿瘤-肌肉对比噪声比增加值(ΔCNR)分别为17±3.8和20±4.4(P=0.34)。
  • 注射后8分钟,Mn-PyC3A与Gd-EOB-DTPA的肝-肿瘤ΔCNR分别为28±9.0和48±23(P=0.11)。
  • Mn-PyC3A给药后在大鼠体内经尿排泄85%、经粪便排泄15%。
  • 注射后1天,Mn和Gd在组织中回收的注射剂量百分比(%ID)分别为0.32±0.12和0.57±0.12(P=0.0030);7天分别为0.058±0.051和0.19±0.052(P<0.0001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The goals of this study were to compare the efficacy of the new manganese-based magnetic resonance imaging (MRI) contrast agent Mn-PyC3A to the commercial gadolinium-based agents Gd-DOTA and to Gd-EOB-DTPA to detect tumors in murine models of breast cancer and metastatic liver disease, respectively, and to quantify the fractional excretion and elimination of Mn-PyC3A in rats.

METHODS: T1-weighted contrast-enhanced MRI with 0.1 mmol/kg Mn-PyC3A was compared with 0.1 mmol/kg Gd-DOTA in a breast cancer mouse model (n = 8) and to 0.025 mmol/kg Gd-EOB-DTPA in a liver metastasis mouse model (n = 6). The fractional excretion, 1-day biodistribution, and 7-day biodistribution in rats after injection of 2.0 mmol/kg [Mn]Mn-PyC3A or Gd-DOTA were quantified by Mn gamma counting or Gd elemental analysis. Imaging data were compared with a paired t test; biodistribution data were compared with an unpaired t test.

RESULTS: The postinjection-preinjection increases in tumor-to-muscle contrast-to-noise ratio (ΔCNR) 3 minutes after injection of Mn-PyC3A and Gd-DOTA (mean ± standard deviation) were 17 ± 3.8 and 20 ± 4.4, respectively (P = 0.34). Liver-to-tumor ΔCNR values at 8 minutes postinjection of Mn-PyC3A and Gd-EOB-DTPA were 28 ± 9.0 and 48 ± 23, respectively (P = 0.11). Mn-PyC3A is eliminated with 85% into the urine and 15% into the feces after administration to rats. The percentage of the injected doses (%ID) of Mn and Gd recovered in tissues after 1 day were 0.32 ± 0.12 and 0.57 ± 0.12, respectively (P = 0.0030), and after 7 days were 0.058 ± 0.051 and 0.19 ± 0.052, respectively (P < 0.0001).

CONCLUSIONS: Mn-PyC3A provides comparable tumor contrast enhancement to Gd-DOTA in a mouse breast cancer model and is more completely eliminated than Gd-DOTA; partial hepatobiliary elimination of Mn-PyC3A enables conspicuous delayed phase visualization of liver metastases.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Erstad DJ, Ramsay IA, Jordan VC, et al. Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A. Invest Radiol. 2019. PMID: 31356382. doi:10.1097/RLI.0000000000000593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。